Chapter 2
Regenerative medicine starts with a deceptively simple question: which cells are being put into the patient, and how do we know? WIA-BIO-020 treats this as the first challenge because every later measurement depends on it. Survival, differentiation and integration figures mean little if the starting population is mislabeled, contaminated or drifting. The standard classifies four cell families, and each has a different set of unresolved problems.
| Type | Source | Potency | Principal difficulty |
|---|---|---|---|
| ESCs | Inner cell mass of the blastocyst (day 5-6 embryo) | Pluripotent | Cellular therapy remains "pending ethical approval"; the specification lists disease modeling and drug screening as the main applications |
| iPSCs | Reprogrammed somatic cells (fibroblasts, blood cells) | Pluripotent | Reprogramming is inefficient (typically 0.01%-3%, depending on method) and the factor set includes an oncogene |
| MSCs | Bone marrow, adipose tissue, umbilical cord, dental pulp | Multipotent | Source-dependent behavior; neurogenic potential is described as limited |
| HSCs | Bone marrow, peripheral blood, umbilical cord blood | Multipotent | Established in transplantation, but defined by marker panels that must be checked each time |
Embryonic stem cells show why potency and risk are linked. They express OCT4, SOX2 and NANOG, are telomerase positive and divide without apparent limit. These traits make them powerful research tools, and they are also what makes an uncontrolled population dangerous. The specification therefore fixes the culture conditions that preserve the phenotype: mTeSR1 or E8 medium, Matrigel or vitronectin as substrate, 37°C and 5% CO₂. Cells are passaged every 3-5 days at 70-80% confluence, and OCT4⁺, NANOG⁺ and SSEA-4⁺ are the pluripotency markers to confirm.
Induced pluripotent stem cells avoid the embryo-related ethical objection and allow patient-specific (autologous) therapy. In exchange, they bring a quality-control burden. The Yamanaka factors are OCT4, SOX2, KLF4 and c-MYC, and the specification spells out c-MYC as a cellular myelocytomatosis oncogene. A population reprogrammed with that factor set cannot be released on a single marker readout. The listed controls are:
Mesenchymal cells present a different identity problem. Four possible tissue origins (BM-MSCs, AD-MSCs, UC-MSCs, DP-MSCs) yield cells that look alike in culture. The specification therefore adopts the ISCT 2006 defining criteria: plastic adherence; at least 95% positivity for CD73, CD90 and CD105; less than 2% expression of CD45, CD34, CD14, CD19 and HLA-DR; and tri-lineage differentiation into osteogenic, adipogenic and chondrogenic cells. A batch that misses any one of these is not, for the purposes of the standard, a conforming MSC product. MSCs are also attractive for their immunomodulatory behavior. They secrete IL-10, TGF-β and PGE2, suppress T-cell proliferation, shift macrophage polarization from M1 toward M2, and show low immunogenicity (low HLA class I and no HLA class II). That behavior is the reason they are used clinically, and it has to be verified rather than assumed.
Hematopoietic stem cells carry the longest clinical track record: bone marrow transplantation, leukemia and lymphoma, sickle cell disease, thalassemia and immune deficiencies. Their identity is CD34⁺, CD133⁺, CD90⁺ and lineage-negative (Lin⁻). From there they branch into a myeloid lineage (red cells, platelets, granulocytes, monocytes) and a lymphoid lineage (T, B and NK cells). Even for this mature field, the safety checklist begins with cell-source authentication: verify line identity and purity above 95%.
The second challenge is measurement. Regenerative therapies are judged by a few quantities that are easy to define and hard to measure consistently, so WIA-BIO-020 gives each a formula and, where the specification supplies one, a threshold.
| Quantity | Definition in the standard | Stated target or range |
|---|---|---|
| Cell survival rate | S = (N_viable / N_total) × 100% | Reported as a percentage |
| Reprogramming efficiency | η = (N_iPSC / N_initial) × 100% | 0.01%-3% typical, method dependent |
| Differentiation efficiency | D_eff = (N_differentiated / N_total) × 100% | >80% for clinical applications |
| Regeneration rate | R = (ΔT / Δt) × E | Cells/day; E is an efficiency factor |
| Proliferation | P = N₀ × e^(rt) | Population at time t |
Each formula hides a methodological choice. Survival depends on what counts as viable and when the count is taken. Differentiation efficiency depends on which marker defines a differentiated cell. The regeneration rate multiplies a volume change per unit time by an efficiency factor E, and that factor is where most of the judgment lies. The standard does not claim these choices disappear. It requires them to be stated next to the number.
The reference implementation expresses that discipline through typed inputs. In the TypeScript SDK a survival assessment names the cell type and the culture conditions along with the raw counts:
import { assessCellSurvival } from '@wia/bio-020';
const survival = assessCellSurvival({
cellType: 'iPSC',
viableCells: 8500000,
totalCells: 10000000,
cultureConditions: 'hypoxic'
});
console.log(survival.survivalRate, survival.viability);With 8,500,000 viable cells out of 10,000,000, the survival formula gives 85%. The same calculation is available from the command line as wia-bio-020 assess-survival --type iPSC --viable 8.5e6 --total 1e7. Regeneration rate takes a tissue type, a cell density, a time frame in days and a list of growth factors. The material's examples use cardiac tissue (1e8 cells/ml over 14 days, with VEGF, FGF and IGF-1) and neural tissue (5e7 over 21 days, with BDNF, NGF and NT-3). The neural example returns a rate in cells/day and a recoveryPercentage. Recording the cell type, culture condition and growth-factor panel with each result means a later reader can tell whether two numbers are comparable.
A graft can contain living, correctly differentiated cells and still fail, because tissue must be connected to the body to persist. This is the hardest gap between laboratory success and clinical benefit, and the standard addresses it with a dedicated metric, the Tissue Integration Score:
I = (V_integrated / V_total) × F_vascular × F_mechanicalThe score runs from 0 to 1. The volume fraction is scaled by a vascular integration factor and a mechanical integration factor, so a graft that is well populated but poorly perfused, or well perfused but mechanically mismatched, cannot score highly. The specification sets a target of I ≥ 0.8. The product form is deliberate: a weakness in either factor drags the whole score down, whereas an additive form would let a strong factor hide a weak one.
The dynamics behind integration are captured by a simple balance model, dT/dt = α × C × G − β × T. Tissue volume T grows in proportion to cell density C and growth factor concentration G, scaled by a regeneration coefficient α, and is lost through a degradation coefficient β. The model shows why a single dose rarely works. If the growth factor drops, the growth term shrinks while degradation continues, and the tissue can regress.
Blood supply is the most common cause of that drop. The standard describes angiogenesis as VEGF binding VEGFR2 and activating ERK1/2 and Akt, which drives endothelial proliferation. Sprouting follows a division of labor. Tip cells follow the VEGF gradient, stalk cells form the lumen, and pericytes stabilize the vessel. Vessel density is measured as vessels per mm², and the specification gives 200-400 vessels/mm² for healthy tissue. A thick engineered construct without a vascular network will starve its core.
Cells must also reach the injury. Migration follows v = μ × ∇C, with velocity proportional to chemotactic sensitivity and the concentration gradient. The listed homing factors are the SDF-1/CXCR4 axis, VEGF, selectins and integrins. Differentiation, in turn, is steered by transcription factors (RUNX2 for bone, PPARG for adipose), epigenetic modifications such as DNA methylation and histone acetylation, and the Wnt, BMP, Notch and Hedgehog pathways.
The scaffold is the physical answer to the vascularization problem. Its required properties are biocompatibility, biodegradability matched to tissue growth, mechanical strength matched to native tissue, and porosity of 70-90% for nutrient diffusion. The SDK exposes a designScaffold function, and the CLI example wia-bio-020 design-scaffold --tissue bone --porosity 0.7 --size 10 sets a 0.7 porosity, the lower edge of the specified range. The key features list names the three organ-repair targets: cardiac, neural and musculoskeletal. Each pairs a different tissue type with a different growth factor panel, as the examples above show.
Growth factors direct the cells, but they are fragile signaling proteins. The specification lists the half-life of most as 2-24 hours, so how and when they are delivered matters as much as which ones are chosen. The reference table pairs each factor with a function, a target cell and an optimal dose range:
| Factor | Function | Target cells | Optimal dose |
|---|---|---|---|
| VEGF | Angiogenesis | Endothelial cells | 10-50 ng/ml |
| FGF-2 | Cell proliferation | Multiple | 5-20 ng/ml |
| TGF-β | ECM production | Fibroblasts | 1-10 ng/ml |
| BMP-2 | Bone formation | Osteoblasts | 50-200 ng/ml |
| PDGF | Wound healing | Fibroblasts | 10-100 ng/ml |
| IGF-1 | Cell growth | Multiple | 50-200 ng/ml |
| EGF | Epithelial growth | Keratinocytes | 5-50 ng/ml |
| BDNF | Neurogenesis | Neurons | 10-100 ng/ml |
| NGF | Nerve growth | Neurons | 50-200 ng/ml |
The doses span a wide range. TGF-β is effective at the low end, 1-10 ng/ml, while BMP-2, IGF-1 and NGF operate in the 50-200 ng/ml band. A protocol written for one factor cannot simply be reused for another.
Three delivery strategies are described, and each trades convenience against control.
The choice depends on the biology. Angiogenesis needs a VEGF signal that persists long enough for vessels to form and stabilize, which a bolus cannot supply. The standard's tooling reflects this by treating delivery as a parameter optimization: wia-bio-020 optimize-gf --target VEGF --concentration 50 --duration 7 takes a target factor, a concentration (50 here, at the upper edge of VEGF's listed range) and a duration in days, and the SDK exposes the same idea as optimizeGrowthFactors. Cardiac cases, for example, combine VEGF, FGF and IGF-1 rather than relying on one signal.
The last challenge is that regenerative products are held to therapeutic standards. WIA-BIO-020 describes its clinical protocols as compliant with the FDA RMAT designation and the EMA ATMP framework, and lists both under regulatory requirements. The practical consequence is that the quantities from sections 2.1 to 2.4 are not only research metrics. Identity checks, viability counts, integration scores and release profiles become the evidence on which a regulator judges a cell or tissue product. Safety conditions follow the same logic: cell-source authentication with purity above 95%, sterile culture at ISO Class 5, and tumorigenicity assessment. Tumorigenicity is the risk behind the teratoma assay for iPSCs and the oncogene caution on c-MYC.
Taken together, the challenges in this chapter form a chain, and each link has a quantity attached:
A failure at any link is not repaired downstream. A well-engineered scaffold cannot compensate for an unauthenticated cell line, and a perfect growth factor schedule cannot rescue a graft that never vascularizes. This is why the standard defines the measurements before the interventions.
The next chapter moves from these problems to the technical foundation that answers them. It examines how the stem-cell, growth-factor, scaffold, clinical-application and quality-control information introduced here is organized into the standard's data format. It also shows how the SDK and CLI functions seen in this chapter carry that structured information, so that a survival figure or an integration score always travels with the context needed to interpret it.